Table 2.

Current evidence, based on data from comparative studies, on the benefits to use belatacept instead of tacrolimus for kidney transplant recipients.

	De novo KTRs	Switch from tacrolimus
Hard, clinically pertinent outcomes
Death with a functioning graft	No proven benefit vs. tacrolimus
Loss of graft function	No proven benefit vs. tacrolimus
Rejections	Higher risk with belatacept than with tacrolimus (Mostly T-cell mediated, mostly within a year after initiation)
Cardiovascular events	No proven benefit vs. tacrolimus
Infectious events	No proven benefit vs. tacrolimus	Higher risk for CMV disease with belatacept
Cancers	No proven benefit vs. tacrolimus
Surrogate endpoints
Estimated GFR	Higher estimated GFR with belatacept than with tacrolimus
Donor specific antibodies	Less de novo DSA with belatacept than with tacrolimus
Glycemic control	Better glycemic control with belatacept than with tacrolimus

GFR, glomerular filtration rate; DSA, donor specific antibodies; KTR, kidney transplant recipient.